Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer

BACKGROUND: As the treatment landscape in patients with non‐small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFRm) continues to evolve, real‐world health utility scores (HUS) become increasingly important for economic analyses. METHODS: In an observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Shirley Xue, Walton, Ryan N., Hueniken, Katrina, Baek, Justine, McCartney, Alexandra, Labbé, Catherine, Smith, Elliot, Chan, Sze Wah Samuel, Chen, RuiQi, Brown, Catherine, Patel, Devalben, Liang, Mindy, Eng, Lawson, Sacher, Adrian, Bradbury, Penelope, Leighl, Natasha B., Shepherd, Frances A., Xu, Wei, Liu, Geoffrey, Hurry, Manjusha, O'Kane, Grainne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912023/
https://www.ncbi.nlm.nih.gov/pubmed/31650705
http://dx.doi.org/10.1002/cam4.2603

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912023/
https://www.ncbi.nlm.nih.gov/pubmed/31650705
http://dx.doi.org/10.1002/cam4.2603

Ejemplares similares